Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular risk factors in patients with polycystic ovary syndrome

Fertil Steril. 2009 Oct;92(4):1372-1377. doi: 10.1016/j.fertnstert.2008.08.016. Epub 2008 Oct 31.

Abstract

Objective: To determine whether or not plasma advanced oxidation protein products (AOPPs) are associated with known cardiovascular risk factors or carotid intima-media thickness (IMT) in patients with polycystic ovary syndrome (PCOS).

Design: A prospective, controlled study.

Setting: University hospital.

Patient(s): Forty-six women with PCOS and 46 age- and body mass index-matched healthy women.

Intervention(s): Carotid IMT was evaluated for both common carotid arteries. We measured serum levels of AOPP, homocysteine (Hcy), C-reactive protein (CRP), malonyldialdehyde (MDA), vitamin B(12), folate, lipid, and hormone profiles. The presence of insulin resistance was investigated by means of homeostasis model assessment (HOMA).

Main outcome measure(s): Serum AOPP, fasting insulin, HOMA index, Hcy, MDA, CRP, and carotid IMT.

Result(s): The women with PCOS had significantly higher serum AOPP than control women. High AOPP was defined as equaling or exceeding the mean + 2 SD of the plasma AOPP in control subjects (56.2 pg/mLl). Carotid IMT, fasting insulin, HOMA index, Hcy, MDA, and CRP were significantly higher in PCOS patients with high AOPP than in those with normal AOPP. Fasting insulin, insulin resistance, and Hcy were independent determinants of plasma AOPP.

Conclusion(s): Increased AOPP may contribute to the increased risk of atherosclerotic cardiovascular disease in women with PCOS.

MeSH terms

  • Adult
  • Blood Proteins / chemistry
  • Blood Proteins / metabolism*
  • Body Mass Index
  • C-Reactive Protein / analysis
  • C-Reactive Protein / metabolism
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / etiology*
  • Case-Control Studies
  • Female
  • Glycation End Products, Advanced / blood*
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Insulin Resistance / physiology
  • Lipids / blood
  • Malondialdehyde / blood
  • Malondialdehyde / metabolism
  • Obesity / blood
  • Obesity / complications
  • Obesity / metabolism
  • Oxidation-Reduction
  • Polycystic Ovary Syndrome / blood*
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / metabolism*
  • Risk Factors
  • Up-Regulation
  • Waist Circumference
  • Young Adult

Substances

  • Blood Proteins
  • Glycation End Products, Advanced
  • Lipids
  • Malondialdehyde
  • C-Reactive Protein